Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

66.42EUR
12:36pm BST
Change (% chg)

€0.55 (+0.83%)
Prev Close
€65.87
Open
€66.11
Day's High
€66.60
Day's Low
€66.03
Volume
893,655
Avg. Vol
2,732,460
52-wk High
€92.97
52-wk Low
€62.88

Select another date:

Wed, Apr 25 2018

BRIEF-FDA Accepts For Review Sanofi's Supplemental Biologics License Application

* FDA ACCEPTS FOR REVIEW SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR 0.5 ML DOSE OF FLUZONE® QUADRIVALENT (INFLUENZA VACCINE) IN CHILDREN 6-35 MONTHS OF AGE

Boehringer's operating income up 20.7 percent on Sanofi deal

FRANKFURT Boehringer Ingelheim, Germany's second-largest drugmaker, posted a gain in operating income of 20.7 percent to 3.5 billion euros (3.06 billion pounds) last year, boosted by the purchase of Sanofi's veterinary medicine.

Boehringer's operating income up 20.7 percent on Sanofi deal

FRANKFURT, April 25 Boehringer Ingelheim, Germany's second-largest drugmaker, posted a gain in operating income of 20.7 percent to 3.5 billion euros ($4.27 billion) last year, boosted by the purchase of Sanofi's veterinary medicine.

UK bans Sanofi epilepsy drug without pregnancy prevention plan

LONDON A Sanofi drug for epilepsy and bipolar disorder linked to thousands of birth defects has been banned in Britain for use in women or girls of child-bearing age, unless they are on a special pregnancy prevention program.

UK bans Sanofi epilepsy drug without pregnancy prevention plan

LONDON A Sanofi drug for epilepsy and bipolar disorder linked to thousands of birth defects has been banned in Britain for use in women or girls of child-bearing age, unless they are on a special pregnancy prevention programme.

UK bans Sanofi epilepsy drug without pregnancy prevention plan

LONDON, April 24 A Sanofi drug for epilepsy and bipolar disorder linked to thousands of birth defects has been banned in Britain for use in women or girls of child-bearing age, unless they are on a special pregnancy prevention programme.

Ex-Roche scientist Reed to head Sanofi R&D as Zerhouni retires

Sanofi said on Tuesday it had hired former Roche top scientist John Reed to head its research operations from July 1, when Elias Zerhouni retires from the French drugmaker.

Ex-Roche scientist Reed to head Sanofi R&D as Zerhouni retires

April 24 Sanofi said on Tuesday it had hired former Roche top scientist John Reed to head its research operations from July 1, when Elias Zerhouni retires from the French drugmaker.

BRIEF-John Reed to replace Zerhouni as Sanofi head of global R&D

* Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years with the company

WHO recommends testing before use of Sanofi's dengue vaccine

PARIS/CHICAGO The World Health Organization (WHO) said on Thursday Sanofi's vaccine against dengue should only be used after testing on individuals to assess whether they have ever been exposed to the infection.

Select another date: